肝脏2023年1月第28卷第1期inpatientswithnon-alcoholicsteatohepatitis:Arandomised,open-labelphaseIItrial.JHepatol,2022,77(3):607-618.[25]LoombaR,LawitzEJ,FriasJP,etal.Safety,pharmacokinetics,andpharmacodynamicsofpegozafermininpatientswithnon-alcoholicsteatohepatitis:arandomised,double-blind,placebo-controlled,phase1b/2amultiple-ascending-dosestudy.LancetGastroenterolHepatol,2023,8(2):120-132.[26]HarrisonSA,ManghiFP,SmithWB,etal.Licogliflozinfornonalcoholicsteatohepatitis:arandomized,double-blind,placebo-controlled,phase2astudy.NatMed,2022,28(7):1432-1438.[27]TakeshitaY,HondaM,HaradaK,etal.ComparisonofTofogliflozinandGlimepirideEffectsonNonalcoholicFattyLiverDiseaseinParticipantsWithType2Diabetes:ARandomized,48-Week,Open-Label,Active-ControlledTrial.DiabetesCare,2022,45(9):2064-2075.[28]ZengRW,YongJN,TanDJH,etal.Meta-analysis:Chemopreventionofhepatocellularcarcinomawithstatins,aspirinandmetformin.AlimentPharmacolTher,2023.[29]徐清扬,范建高.肾素-血管紧张素系统抑制剂治疗非酒精性脂肪性肝病的研究进展.肝脏,2022,27(11):1161-1163.[30]Sun...